Geron
Geron is a biopharmaceutical company focused on developing treatments for blood cancers through telomerase inhibition, with its lead product candidate, imetelstat, currently in Phase 3 clinical trials.
Services
Geron focuses on developing treatments for blood cancers through telomerase inhibition. They provide access to their investigational therapies via an Expanded Access Protocol in the U.S. for eligible patients with lower-risk myelodysplastic syndromes. Additionally, Geron engages in partnerships to advance scientific understanding and treatments related to telomere biology.
Products
Geron is developing imetelstat, a first-in-class investigational telomerase inhibitor. Imetelstat is currently being explored for its potential across multiple hematologic malignancies. The company is conducting two Phase 3 clinical trials with registrational intent to further evaluate the efficacy and safety of imetelstat.
Clinical Trials
Geron is conducting two Phase 3 clinical trials with registrational intent for imetelstat. These trials aim to study the effects and potential benefits of imetelstat across various hematologic malignancies. Access to the treatment is also available through an Expanded Access Protocol for eligible patients in the U.S. with lower-risk myelodysplastic syndromes.
Locations
Geron is headquartered in Foster City, California, and also has an office in Parsippany, New Jersey. These locations support the company's operations, research, and development activities.
Research and Development Partnerships
Geron engages in partnerships to advance scientific understanding and potential treatments in telomere biology. These collaborations help further explore the therapeutic potential of their investigational products, including imetelstat.